Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Almac Group Ltd.’s Diagnostics Business Unit today announced the validated results of the ALM AADx assay, a gene expression test that identifies a subgroup of high grade serous ovarian cancer (HGSOC) patients that have a good prognosis following ...
read more
As the Industry faces the tightest ever new heavy metal mandates from the FDA, stipulating the control and documentation, where appropriate, of all elemental impurities in drug products, drug substances and excipients, Almac has invested in state of ...
read more
Craigavon-based pharmaceutical development company Almac recorded pre-tax profits of £19.2m in 2013, up around 30% on the previous year, it has announced.
read more
Almac has been recognised for its cutting edge technological developments, scooping a top award at the recent Belfast Telegraph Northern Ireland Business Awards 2012, in association with British Midland International (bmi).
read more
Almac’s diagnostics business unit today announced that it has received a Clinical Laboratory Permit from the New York State Department of Health, allowing them to receive patient samples for clinical testing from New York.
read more
Almac are pleased to announce the launch of their novel “Direct to Patient” shipping service for clinical trials recognising the shift in market trends to introduce as many efficiencies as possible into the management of clinical trials and the ...
read more
Dedicated temperature and humidity controlled labelling suites go live in USA and Europe as business from biosimilars and biologics clinical studies expands
read more
Wednesday, March 13, 2024
Allumiqs and Prolytix, announced a long-term, strategic partnership focused on delivering collaborative and integrated solutions to help customers optimize drug development pipelines.
read more
Monday, November 30, 2020
Allos Pharma has announced the exclusive license rights on arbaclofen in Fragile X Syndrome.
read more
Thursday, February 23, 2023
AllCells®, a Discovery Life Sciences™ company announced the expansion of its apheresis network with the addition of two new centers in Houston, Texas, and Huntsville, Alabama. These new centers complement AllCells' existing presence in two major U.S....
read more
Tuesday, November 12, 2019
Alkermes announced the receipt of a $150 million milestone payment from Biogen triggered by the recent FDA approval of VUMERITY.
read more
Wednesday, April 17, 2013
Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for ...
read more
PCI Synthesis, Inc. (www.pcisynthesis.com), a 12-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, today announced that industry veteran ...
read more
Alembic is voluntarily recalling one lot of Telmisartan Tablets, USP, 20 mg, packaged in 30-count bottles, Lot No. 1905005661 to the consumer level.
read more
Alcami announces the Missouri House of Representatives and St. Louis Mayor Lyda Krewson will honor Alcami with a resolution and letter of commendation.
read more